Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Typical antipsychotic Stories

2010-08-05 12:00:00

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, after peaking at $6.3 billion in 2011, the schizophrenia drug market will decline to $5.2 billion in 2019, owing to the loss of patent protection for most atypical antipsychotics on the market. The Pharmacor 2010 findings from the topic entitled Schizophrenia reveal that the generic erosion of key agents -- most notably...

2010-05-21 07:00:00

TITUSVILLE, N.J., May 21 /PRNewswire/ -- New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone long-acting therapy), also an injectable medicine to treat schizophrenia, will be presented next week at a major psychiatry meeting in New Orleans. Posters on this data will be presented on Wednesday, May 26, from 12 noon to...

2010-05-19 11:00:00

ORLANDO, Fla., May 19 /PRNewswire-FirstCall/ -- In growing numbers, children across America are adding a dose of medicine to their daily routine. In 2009, drug trend for children - a measure of prescription spending growth - increased 10.8 percent, driven by a 5 percent increase in drug utilization and higher medication costs, according to the Medco 2010 Drug Trend Report. The growth in prescription drug use among children was nearly four times higher than the rise seen in the overall...

2010-04-12 07:00:00

WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Janssen's Invega Sustenna earns Decision Resources' proprietary clinical gold standard status for the treatment of schizophrenia in 2013. Invega Sustenna has competitive advantages in safety, tolerability and delivery over current and emerging therapies. "Invega Sustenna, which launched in the second half of 2009, was the...

2010-02-23 08:00:00

WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the world's major pharmaceutical markets, emerging oral atypical antipsychotics will compete against each other and against established drugs for the same niche patient population in the treatment of schizophrenia. The Pharmacor 2010 findings from the topic entitled Schizophrenia reveals that emerging oral atypical...

2010-01-11 20:57:42

A study published today in the Archives of Internal Medicine examines the impact of a safety warning issued by the Food and Drug Administration for commonly prescribed antipsychotic medications. The results show the warnings resulted in a decline in usage among the elderly with dementia, yet raise the question as to whether the FDA's system of communicating these warnings is sufficiently targeted and effective. "Because this medication class has limited evidence of benefit among the elderly...

2010-01-11 20:14:57

Older adults newly admitted to nursing homes with high rates of antipsychotic prescribing in the previous year are more likely to receive antipsychotic agents, according to a report in the January 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Of these treated patients, some had no identified clinical indication for this therapy. In 2007, almost one-third of U.S. nursing home residents received antipsychotic drugs, according to background information in the...

2010-01-11 20:09:53

The use of atypical antipsychotics to treat elderly patients with dementia appears to have decreased following a 2005 Food and Drug Administration (FDA) advisory regarding the risks of these medications in this population, according to a report in the January 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Clozapine, the first second-generation or "atypical" antipsychotic medication, was introduced in the United States in 1989, according to background information...

2009-12-14 07:30:00

INDIANAPOLIS, Dec. 14 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company (NYSE: LLY) announced today. ZYPREXA RELPREVV, a long-acting intramuscular injection, sustains the delivery of olanzapine for up to four weeks. Different from both oral and injected short-acting formulations, long-acting formulations of antipsychotics...

2009-12-10 06:57:00

TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week. An estimated one percent of the world's population suffers from schizophrenia - a brain disorder that impairs a person's...